(Alliance News) - AstraZeneca PLC and Amgen Inc on Thursday announced positive top-line results from the phase 3 Crossing trial of tezepelumab in patients living with eosinophilic esophagitis. Read More
(Alliance News) - on Thursday, as markets await the imminent start of the Jackson Hole summit and Federal Reserve Chair Kevin Warsh's Friday speech. Read More
Daiichi Sankyo Co Ltd and AstraZeneca PLC - pharmaceutical companies based in Tokyo and Cambridge, respectively - The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway, generic name datopotamab deruxtecan, plus either AstraZeneca's rilvegostomig or Datroway monotherapy versus current standard of care as an adjuvant treatment. Patients under study are diagnosed with muscle-invasive urothelial cancer at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. Datroway was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. The partners are also evaluating Datroway plus platinum-based chemotherapy compared to gemcitabine and platinum-based chemotherapy in patients with metastatic urothelial carcinoma following progression during or after treatment with enfortumab vedotin in combination with pembrolizumab in the TROPION-Urothelial03 phase 2/3 trial. Read More
(Alliance News) - London's FTSE 100 faded into the close on Wednesday, posting modest losses, as a strong US inflation print knocked sentiment ahead of Nvidia earnings. Read More
(Alliance News) - The FTSE 100 closed higher on Tuesday as oil prices fell and investors geared up for Wednesday's double bill of earnings from Nvidia and US inflation data. Read More
(Alliance News) - AstraZeneca PLC on Tuesday announced that its subsidiary AstraZeneca Finance LLC had priced four tranches of eurobonds. Read More
(Alliance News) - The FTSE 100 was called higher on Tuesday, while Germany's gross domestic product "is maintaining the growth momentum" as its on-year rise surpassed an earlier estimate. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
(Alliance News) - The FTSE 100 was called slightly higher on Monday, following news of US President Donald Trump's intention to wage a "crushing" financial operation against Iran. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - JD Sports Fashion lowers its annual profit guidance after weak second-quarter trading. Standard Life unveils a GBP2 billion-backed partnership to expand its UK pension risk transfer business, while Hays swings to an annual loss. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday. Read More
(Alliance News) - The FTSE 100 outperformed European peers on Tuesday, with oil stocks on the up amid rising prices, and bond market concerns adding to the cautious mood. Read More
(Alliance News) - Stock prices in London opened slightly higher on Tuesday, but trade was cautious as Middle East sabre-rattling continues, while sterling faded after a weaker UK unemployment reading. Read More
(Alliance News) - AstraZeneca PLC on Monday announced it is discontinuing the eVOLVE-Lung02 phase III trial after an independent review found its experimental drug volrustomig was unlikely to improve outcomes against the comparator treatment. Read More
(Alliance News) - AstraZeneca says it has halted one trial but reports promising findings from two other ones, Telecom Plus maintains its annual outlook while AIM-listed Time Finance has agreed to a takeover. Read More
(Alliance News) - Stocks in London closed mixed on Friday, with weak mining and pharmaceutical stocks dragging the blue-chip FTSE 100 lower, but mid-caps posting modest gains. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday said Enhertu, which it is developing alongside AstraZeneca PLC, received another approval in China. Read More
(Alliance News) - The FTSE 100 fell on Thursday despite well-received earnings, but mid-caps extended their recent gains, lifted by advances by WPP and easyJet. Read More